Login to Your Account



Bone Therapeutics halts bone regeneration cell therapy trial on interim efficacy data

By Cormac Sheridan
Staff Writer

Wednesday, September 20, 2017

DUBLIN – Bone Therapeutics SA is calling an early halt to a phase I/IIa trial of its Allob allogeneic cell therapy in patients with slow-to-heal bone fractures following an interim analysis that showed the therapy exceeded expectations.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription